Company profile: Magstim
1.1 - Company Overview
Company description
- Provider of Transcranial Magnetic Stimulation (TMS) stimulators and packages for Magstim TMS therapy and neuromodulation research. Offers Magstim TMS Therapy for depression, StimGuide for precise TMS delivery, and Neurosign intraoperative nerve monitoring solutions. Provides installation, certification training, and dedicated engineering service and support. Magstim stimulators are used in the majority of published TMS research.
Products and services
- Magstim® TMS Therapy: A non-invasive outpatient treatment for depression, using repetitive magnetic pulses to stimulate brain cells, used for Magstim TMS therapy
- StimGuide: A clinical-setting device engineered to enhance the precision and effectiveness of TMS treatment, supporting accurate delivery during Magstim therapy procedures
- Neurosign®: An operating-room-grade intraoperative nerve monitoring system that delivers high quality and cost-effectiveness tailored for operating room environments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Magstim
Beckley Psytech
HQ: United Kingdom
Website
- Description: Provider of psychedelic medicine R&D focused on mental health, developing investigational therapies including BPL-003, a synthetic intranasal 5-MeO-DMT for Treatment Resistant Depression and Alcohol Use Disorder, and ELE-101, an intravenous psilocin for Major Depressive Disorder; exploring the therapeutic potential of psilocybin and other compounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Beckley Psytech company profile →
Wallaby Medical
HQ: United States
Website
- Description: Provider of the Avenir coil system and medical devices for stroke treatment, operating as a manufacturing company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Wallaby Medical company profile →
Torrey Pines Therapeutics
HQ: United States
Website
- Description: Provider of small molecule drug discovery and development in the United States, with a portfolio comprising candidates from proprietary drug-targeting platforms and in-licensed/acquired programs. As of August 31, 2010, the company's pipeline includes three clinical development programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Torrey Pines Therapeutics company profile →
Saegis Pharma
HQ: United States
Website
- Description: Provider of medicines in development for behavioral disorders, with a pipeline of treatments for central nervous system diseases involving cognitive dysfunction, including Alzheimer’s disease, mild cognitive impairment, and attention deficit hyperactivity disorder.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Saegis Pharma company profile →
Contineum Therapeutics
HQ: United States
Website
- Description: Provider of novel oral small molecule therapies for neuroscience, inflammation, and immunology, including PIPE-791, an LPA1R antagonist in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PMS); PIPE-307, a selective M1 receptor inhibitor in development for relapsing-remitting multiple sclerosis (RRMS) and depression; and LPA1R DC, a peripherally restricted LPA1R antagonist.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Contineum Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Magstim
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Magstim
2.2 - Growth funds investing in similar companies to Magstim
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Magstim
4.2 - Public trading comparable groups for Magstim
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →